Protara Therapeutics (TARA) closed its public offering of securities, raising $100 million in gross proceeds.
The offering comprised about 13.7 million common shares at $6.25 apiece and prefunded warrants to purchase about 2.33 million shares at $6.249 per warrant, the company said Wednesday in a statement.
Underwriters have a 30-day overallotment option to acquire up to 2.4 million additional shares.
Protara plans to use the net proceeds to fund the clinical development of TARA-002, among other things. TARA-002 is an investigational cell therapy in development for the treatment of nonmuscle invasive bladder cancer and lymphatic malformations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。